Sex: F
Vaccine: FLUX, FLUX
Symptoms: Pain, Red blood cell sedimentation rate normal, Renal function test normal, Rhabdomyolysis, Upper respiratory tract infection
Clinical narrative: Rhabdomyolysis; Rhabdomyolysis; This case was reported in a literature article and described the occurrence of rhabdomyolysis in a adult female patient who received Flu unspecified (Influenza vaccine) for prophylaxis.  Co-suspect products included Flu unspecified (Influenza vaccine) for prophylaxis.   The patient's past medical history included systemic lupus erythematosus (Family History) (maternal). Concurrent medical conditions included cystic acne, muscle pain and weakness (frequent episodes).   On an unknown date, the patient received Influenza vaccine and Influenza vaccine. On an unknown date, unknown after receiving Influenza vaccine and not applicable after receiving Influenza vaccine, the patient experienced rhabdomyolysis (serious criteria hospitalization and GSK medically significant) and rhabdomyolysis (serious criteria hospitalization and GSK medically significant). Rechallenge with Influenza vaccine was positive. On an unknown date, the outcome of the rhabdomyolysis and rhabdomyolysis were recovered/resolved.   The reporter considered the rhabdomyolysis and rhabdomyolysis to be possibly related to Influenza vaccine and Influenza vaccine.     Additional Information: GSK Receipt Date: 22-Aug-2022 Author's comment: The patient was 46 years old at the time of reporting.  The patient's family history included maternal systemic lupus erythematous. Patient had a history of cystic acne and most notably, frequent episodes of muscle aches and weakness.  In 2006 and 2016, the patient was hospitalized for episodes of rhabdomyolysis after receiving influenza vaccine. Autoimmunemyositis was ruled out. The patient never received statin medication. In late 2017, the patient was admitted for rhabdomyolysis after upper respiratory tract infection. The patient reported dark urine but no rash or arthralgia. Patient had elevated creatinine kinase (CK) 107,737 U/L, Aspartate transaminase (AST) 379 U/L, and alanine transaminase (ALT) 115 U/L. The patient's renal function, sedimentation rate, Thyroid stimulating hormone, Human immunodeficiency virus (HIV), influenza, direct Coombs, protein electrophoresis, and antinuclear antibodies were negative or within normal limits. The patient was treated with intravenous fluids, pain medication, and discharged.  At the time of presentation, she was evaluated for generalized body aches five days after receiving second dose of COVID mRNA-1273 (Moderna) vaccine and was admitted for rhabdomyolysis. Six months prior to that, the patient received her first dose of Ad26 (Johnson & Johnson) vaccine without sequelae. Patient was discharged as she was asymptomatic and CK had dropped significantly. Rhabdomyolysis can be an adverse event to vaccine administration, most commonly influenza vaccination. The patient had a history of recurrent episodes of rhabdomyolysis after receiving influenza and COVID immunizations, as well as viral infection.  Additional supportive information: This article corresponding to this case is not available for regulatory submission due to copyright restriction.